Clinical outcomes varied among KRAS-mutated subtypes, with 7 cases developing metastatic disease and resistance to current treatment strategies, highlighting the need for subtype-specific diagnostic criteria and therapeutic strategies. This evidence concerns the gene KRAS and metastatic neoplasm.